Dermal inorganic gadolinium concentrations: Evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis

British Journal of Dermatology

Volumn 158, Issue 2, 2008, Pages 273-280

  Abraham, J L ^a   Thakral, C ^a   Skov, L ^b   Rossen, K ^b   Marckmann, P ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Contrast agents; Energy dispersive X ray spectroscopy; Gadolinium; Nephrogenic systemic fibrosis; Scanning electron microscopy; Transmetallation

Indexed keywords

CALCIUM; CALCIUM ION; GADODIAMIDE; GADOLINIUM; PHOSPHORUS; SODIUM;

ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HUMAN; MALE; METALLATION; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; ROENTGEN SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SKIN BIOPSY; SKIN DISEASE;

ADULT; AGED; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM DTPA; HUMANS; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SKIN; SKIN DISEASES; SPECTROMETRY, X-RAY EMISSION;

EID: 38349103948     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08335.x     Document Type: Article

References (31)

1. Runge VM. Gd-DTPA: an i.v. contrast agent for clinical MRI. Int J Rad Appl Instrum B 1988 15 : 37 44.
2. Cowper SE, Robin HS, Steinberg SM et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000 356 : 1000 1.
3. Cowper SE, Su LD, Bhawan J et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001 23 : 383 93.
4. Levine JM, Taylor RA, Elman LB et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004 30 : 569 77.
5. Ting WW, Stone MS, Madison KC et al. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003 139 : 903 6.
6. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003 139 : 928 30.
7. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006 21 : 1104 8.
8. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003 25 : 358.
9. High WA, Ayers RA, Chandler J et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007 56 : 21 6.
10. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007 56 : 27 30.
11. Marckmann P, Skov L, Rossen K et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006 17 : 2359 62.
12. Thakral C, Abraham JL. Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of gadolinium deposits in skin. J Electron Microsc 2007; doi: (E-pub 19 October 2007).
13. Conner TL, Norris GA, Landis MS et al. Individual particle analysis of indoor, outdoor and community samples from the 1998 Baltimore particulate matter study. Atmos Environ 2001 35 : 3935 46.
14. Marckmann P, Skov L, Rossen K et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007 22 : 3174 8.
15. Tweedle MF, Eaton SM, Eckelman WC et al. Comparative chemical structure and pharmacokinetics of MRI contrast agents. Invest Radiol 1988 23 (Suppl. 1 S236 9.
16. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 1992 10 : 641 8.
17. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990 8 : 467 81.
18. Kimura J, Ishiguchi T, Matsuda J et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat Med 2005 23 : 322 6.
19. Idee JM, Port M, Raynal I et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006 20 : 563 76.
20. Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol 1996 31 : 739 42.
21. O'Neill WC. Vascular calcification: not so crystal clear. Kidney Int 2007 71 : 282 3.
22. Yerram P, Saab G, Karuparthi PR et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007 2 : 258 63.
23. Evans CH. Biochemistry of the Lanthanides, Vol. 8. New York : Plenum Press, 1990.
24. Mizgerd JP, Molina RM, Stearns RC et al. Gadolinium induces macrophage apoptosis. J Leukoc Biol 1996 59 : 189 95.
25. Franano FN, Edwards WB, Welch MJ et al. Biodistribution and metabolism of targeted and nontargeted protein-chelate-gadolinium complexes: evidence for gadolinium dissociation in vitro and in vivo. Magn Reson Imaging 1995 13 : 201 14.
26. Harpur ES, Worah D, Hals PA et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 1993 28 (Suppl. 1 S28 43.
27. Hart HE, Greenberg J, Lewis R et al. Metabolism of lanthanum and yttrium chelates. J Lab Clin Med 1955 46 : 182 92.
28. Duncan JR, Franano FN, Edwards WB et al. Evidence of gadolinium dissociation from protein-DTPA-gadolinium complexes. Invest Radiol 1994 29 (Suppl. 2 S58 61.
29. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006 41 : 272 8.
30. Spasovski GB, Sikole A, Gelev S et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006 21 : 2217 24.
31. Hirano S, Suzuki KT. Exposure, metabolism, and toxicity of rare earths and related compounds. Environ Health Perspect 1996 104 (Suppl. 1 85 95.